Arcus Biosciences Has Favorable Setup After Merck Belzutifan Failure, Wedbush Says

MT Newswires Live02:12

Arcus Biosciences (RCUS) shares have a favorable setup following Merck's (MRK) belzutifan phase 3 failure in Litespark-012, with Wedbush Securities saying the readout does not represent negative readthrough for Arcus' casdatifan and highlights a differentiated profile in clear cell renal cell carcinoma, or RCC.

The brokerage said in a Tuesday note that the Merck data do not impact Arcus' TKI-free frontline strategy and that casdatifan remains supported by a more optimal development approach and stronger comparative efficacy versus belzutifan.

Wedbush also said recent weakness following the discontinuation of Arcus' domvanalimab program has created an attractive entry point ahead of upcoming clinical data readouts, reinforcing a favorable setup for the stock.

The firm reiterated its outperform rating on the stock and price target of $41 per share.

Price: 23.31, Change: +0.57, Percent Change: +2.51

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment